Vemurafenib companion diagnostic - Roche/Plexxikon

Drug Profile

Vemurafenib companion diagnostic - Roche/Plexxikon

Alternative Names: cobas 4800 BRAF V600 Mutation Test

Latest Information Update: 15 Apr 2015

Price : $50

At a glance

  • Originator Plexxikon; Roche Diagnostics
  • Developer Roche Diagnostics
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma

Most Recent Events

  • 02 Dec 2014 Registered for Malignant melanoma (Diagnosis) in Japan (unspecified route)
  • 02 Dec 2014 Registered for Diagnostic tests in Japan (unspecified route)
  • 06 Dec 2012 Roche plans a non-interventional study for Malignant melanoma diagnosis in France (NCT01744860)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top